FY2026 EPS Estimates for AXSM Decreased by Cantor Fitzgerald

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Cantor Fitzgerald cut their FY2026 earnings estimates for shares of Axsome Therapeutics in a note issued to investors on Tuesday, September 16th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($2.54) per share for the year, down from their previous forecast of ($2.27). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

AXSM has been the subject of several other research reports. Royal Bank Of Canada upped their target price on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. Morgan Stanley assumed coverage on shares of Axsome Therapeutics in a report on Thursday, July 3rd. They set an “overweight” rating and a $190.00 price objective for the company. Bank of America lifted their price objective on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Oppenheimer started coverage on shares of Axsome Therapeutics in a research note on Tuesday, June 3rd. They issued an “outperform” rating and a $185.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $150.00 target price on shares of Axsome Therapeutics in a research note on Monday, August 4th. Two research analysts have rated the stock with a Strong Buy rating and thirteen have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $177.86.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $118.63 on Thursday. Axsome Therapeutics has a 1 year low of $75.56 and a 1 year high of $139.13. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.51. The firm has a market cap of $5.92 billion, a price-to-earnings ratio of -23.40 and a beta of 0.54. The company has a fifty day moving average price of $112.74 and a 200-day moving average price of $110.51.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.08. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The firm had revenue of $150.04 million during the quarter, compared to analyst estimates of $140.02 million.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AXSM. Cetera Investment Advisers lifted its holdings in shares of Axsome Therapeutics by 19.5% in the fourth quarter. Cetera Investment Advisers now owns 7,109 shares of the company’s stock worth $601,000 after buying an additional 1,160 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Axsome Therapeutics by 4.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,921 shares of the company’s stock worth $1,770,000 after buying an additional 986 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Axsome Therapeutics by 118.1% in the fourth quarter. Nuveen Asset Management LLC now owns 221,202 shares of the company’s stock worth $18,716,000 after buying an additional 119,780 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Axsome Therapeutics by 30.3% in the fourth quarter. ProShare Advisors LLC now owns 12,664 shares of the company’s stock worth $1,072,000 after buying an additional 2,942 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in shares of Axsome Therapeutics by 85.3% in the fourth quarter. Two Sigma Advisers LP now owns 6,300 shares of the company’s stock worth $533,000 after buying an additional 2,900 shares in the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 45,783 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $114.48, for a total transaction of $5,241,237.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark E. Saad sold 9,127 shares of the company’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $125.07, for a total transaction of $1,141,513.89. Following the sale, the director directly owned 10,002 shares in the company, valued at approximately $1,250,950.14. This trade represents a 47.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 193,962 shares of company stock valued at $22,849,208. Insiders own 22.30% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.